Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy …

D Marinelli, A Nuccio, A Di Federico, F Ambrosi… - Journal of Thoracic …, 2024 - Elsevier
Background Neoadjuvant chemoimmunotherapy has reshaped the treatment landscape for
resectable NSCLC, yet the prognostic significance of pathologic response remains unclear …

[HTML][HTML] Evolving insights in blood-based liquid biopsies for prostate cancer interrogation

RD Bonfil, G Al-Eyd - Oncoscience, 2023 - ncbi.nlm.nih.gov
During the last decade, blood sampling of cancer patients aimed at analyzing the presence
of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic …

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC

B Wang, B Zou, S Xu, C Zhao, J Pei, S Wang… - Frontiers in …, 2023 - frontiersin.org
Background To date, identifying resectable stage I non-small cell lung cancer (NSCLC)
patients likely to benefit from adjuvant therapy (ADT) remains a major challenge. Previous …

An integrative analysis of DNA methylation and gene expression to predict lung adenocarcinoma prognosis

L Xu, Z Huang, Z Zeng, J Li, H **e, C **e - Frontiers in Genetics, 2022 - frontiersin.org
Background: Abnormal DNA methylation of gene promoters is an important feature in lung
adenocarcinoma (LUAD). However, the prognostic value of DNA methylation remains to be …